Päivi Östling has more than 10 years of research experience in the field of precision cancer medicine research. She has been responsible for establishing a functional precision medicine (fPM) platform at Science for Life Laboratory (SciLifeLab) and Karolinska Institutet (KI) through the Olli Kallioniemi research group where she also acts as a co-principal investigator. Their research focuses on individualized drug profiling including multi-omics in acute myeloid leukemia, ovarian, bladder and pediatric tumors. Since June 2021, she is one of the Scientific Leads of Precision Medicine at SciLifeLab that aims to enable services for next-generation precision medicine. She also holds key positions of trust at the boards of Cancer Research KI, Karolinska Comprehensive Cancer Center, SWELife and Genomic Medicine Sweden (GMS). Through her research focus, her experience in establishing research infrastructure for precision medicine and her commissions of trust she is well-placed to provide valuable insights into the complex landscape of precision medicine. In her presentation she will focus on how drug profiling combined with other omics can provide for measurable data-driven hallmarks of AML biology and touch upon strategies towards future strategies for PM.